Hillstream BioPharma Announces Two Abstracts Accepted for Presentation at AACR 2021 Annual Meeting

February 25th, 2021

Abstracts highlight data from HSB-1216 in small cell lung cancer and in combination with low-dose chemotherapy in triple negative breast cancer

Bridgewater, NJ – February 25, 2021 – Hillstream BioPharma, Inc. (“Hillstream”) today announced that two abstracts highlighting the progress of HSB-1216  will be presented as an e-poster at the 2021 American Association for Cancer Research (AACR) Virtual Annual Meeting taking place from April 10-15 and May 17-21, 2021.

The accepted abstracts, to be released on March 10, 2020 at 4:30 pm EDT, summarize nonclinical research in which HSB-1216 is studied as a single agent in chemotherapy-resistant small cell lung cancer and in combination with doxorubicin in triple negative breast cancer.  “We are actively evaluating the potential utility of HSB-1216 in several solid tumor types,” stated Randy Milby, President and CEO of Hillstream BioPharma.  “Independent emerging research confirms our own studies regarding the novel mechanism of HSB-1216, and we are pleased to share our latest updates at this year’s AACR meeting, as we focus on progressing this compound to the clinic as soon as possible.”

The e-poster website will be launched April 10, 2021, the first day of the AACR Virtual Annual Meeting.  All e-posters will be made available for browsing on this date and will remain available for viewing through June 21st. The two Hillstream BioPharma sponsored presentations include:

Abstract Number 3107: HSB-1216 A Novel Agent for the Treatment of Chemotherapy-Resistant ES-Small Cell Lung Cancer

  • Session Type: E-Poster Session
  • Session Category: Tumor Biology
  • Session Title: Stem Cells Biology

Abstract Number 3082: Synergistic Inhibition of TNBC cell growth by novel doxorubicin/salinomycin – encapsulated dual drug nanoparticles

  • Session Type: E-Poster Session
  • Session Category: Tumor Biology
  • Session Title: Stem Cells Biology

The two Hillstream BioPharma-sponsored abstracts will be published online in the Proceedings supplement to AACR journal, Cancer Research, after completion of the AACR Virtual Annual Meeting and will be accessible on the Hillstream website (tharimmune.com).

About HSB-1216
HSB-1216 is a novel and potent inducer of a powerful mechanism called ferroptosis.  This process, which sequesters iron in lysosomes, allows HSB-1216 to cause lysosomal membrane permeabilization of hard-to-treat cancer cells – causing them to rupture and stop replicating.  An area of interest for the development of HSB-1216 is small cell lung cancer and other rare cancers with high unmet need.  HSB-1216 uses the Quatramer delivery platform.  The Quatramer is a tumor-targeted platform with capacity to deliver drug and biologic combinations.  Quatramer enhances the uptake of HSB-1216 in the tumor microenvironment with an extended duration of action and minimal off-target toxicity.  Quatramer offers the potential to significantly improve the profile and widen the therapeutic window of HSB-1216 and other small molecules, peptides, cytokines and oligomers preferentially delivered to tumors. Quatramer building blocks are pH-triggered to degrade intra-cellularly and are comprised of FDA inactive ingredients.

About Hillstream BioPharma Inc.
Hillstream BioPharma Inc. (“Hillstream”, “Company”) is a development-stage company focused on rare cancers.  By harnessing a weakness in tumors to preferentially concentrate Hillstream’s Quatramer technology, we are developing targeted cancer therapies.  The Company is advancing lead candidates, including novel small molecules and proprietary DNA expression vectors which encode inflammatory cytokines directly into tumor’s genome.  Hillstream is working to improve the lives of patients and rapidly move into the clinic to treat small cell lung cancer, soft tissue sarcoma and other unmet need rare cancers.  For more information, please visit tharimmune.com.

Forward Looking Statements
This press release includes forward-looking statements including, but not limited to, statements related to the development of drug candidates, our operations and business strategy, our expected financial results, and corporate updates. The forward-looking statements contained in this press release are based on management’s current expectations and are subject to substantial risks, uncertainty and changes in circumstances. Actual results may differ materially from those expressed by these expectations due to risks and uncertainties, including, among others, those related to our ability to obtain additional capital on favorable terms to us, or at all, including, without limitation, to fund our current and future preclinical studies and clinical trials and the success, timing and cost of our drug development program and our ongoing or future preclinical studies and clinical trials, including, without limitation, the possibility of unfavorable new clinical and preclinical data and additional analyses of existing data, that the risks that prior clinical and preclinical results may not be replicated, and risks associated with the current coronavirus pandemic.  Forward-looking statements speak only as of the date of this press release, and we undertake no obligation to review or update any forward-looking statement except as may be required by applicable law.

Hillstream BioPharma Inc.
Randy Milby
President & CEO
Hillstream Biopharma Inc.
Tel: +1 302.743.2995
Email: rmilby@tharimmune.com

Investor Contact:
Jennifer K. Zimmons, Ph.D.
Investor Relations
Zimmons International Communications
Tel: +1 917.214.3514
Email: jzimmons@zimmonsic.com